|
Affiliation |
Faculty of Medicine College Hospital Department of Gastroenterology |
|
Title |
Lecturer |
|
External Link |
|
HASUIKE Satoru
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 2005.6 宮崎大学 )
-
学士（医学） ( 1994.3 宮崎大学 )
Papers 【 display / non-display 】
-
Inflammatory Hepatocellular Adenoma Mimicking Focal Nodular Hyperplasia that Grew during Pregnancy and Changed its Appearance on Magnetic Resonance Imaging after Delivery Reviewed
Hasuike Satoru, Nagata Kenji, Sasaki Haruka, Hirata Tomoya, Suzuki Sho, Komaki Yuri, Ozono Yoshinori, Nakamura Kenichi, Miike Tadashi, Iwakiri Hisayoshi, Sueta Mitsue, Yamamoto Shojiro, Maekawa Kazuya, Kawakami Hiroshi
Internal Medicine advpub ( 0 ) 2023.4
Authorship：Lead author Language：English Publishing type：Case report Publisher：The Japanese Society of Internal Medicine
-
A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib Reviewed
Kimura S., Fujisaki Y., Onizuka C., Hasuike S., Sato Y., Mukai S., Kamoto T.
IJU Case Reports 2023
Language：English Publishing type：Case report Publisher：IJU Case Reports
Introduction: Although the incidence of hyperammonemia as an adverse event of tyrosine kinase inhibitors is quite low, several cases of tyrosine kinase inhibitor associated hyperammonemia have been reported. We report a case of hyperammonemia, that occurred during combined treatment with axitinib and pembrolizumab in a metastatic renal cell carcinoma patient without hepatic disorder or liver metastases. Case presentation: A 77-year-old Japanese woman was diagnosed with metastatic renal cell carcinoma and was treated with pembrolizumab and axitinib. Both agents were subsequently discontinued due to hyperammonemia with hypothyroidism. After recovery, the patient resumed single-agent therapy with axitinib. However, hyperammonemia and hypothyroidism occurred again, suggesting axitinib-inducible adverse event. After nephrectomy, a lower dose of axitinib was restarted and continued safely for residual metastases under prophylactic treatment with aminoleban, lactulose, and levothyroxine. Conclusion: The rare occurrence of hyperammonemia should be considered during treatment with VEGFR- targeted tyrosine kinase inhibitor including axitinib, and supportive prophylactic medication may be useful.
DOI： 10.1002/iju5.12586
-
Komaki Y., Ozono Y., Nakamura K., Iwakiri H., Hasuike S., Sueta M., Miike T., Yamamoto S., Uto H., Kusumoto K., Ochiai T., Kato J., Komada N., Kuroki K., Eto T., Shigehira M., Hirono S., Nagata K., Kawakami H.
BMC Gastroenterology 22 ( 1 ) 210 2022.12
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：BMC Gastroenterology
Background: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥ 75 years. Methods: This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G/P treatment were collected from medical records. The patients were divided into two groups: younger (n = 199, aged < 75 years) and older (n = 72, aged ≥ 75 years). Virological data and AEs were analyzed according to the age group. Results: In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (P = 0.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups. Conclusions: Compared with younger patients, older patients showed similar virological response and tolerance to G/P treatment.
-
Uchida K., Ozono Y., Uchiyama N., Hatada H., Nakamura K., Komaki Y., Iwakiri H., Hasuike S., Nagata K., Sato Y., Kawakami H.
Medicine (United States) 101 ( 35 ) e30486 2022.9
Language：Japanese Publishing type：Case report Publisher：Medicine (United States)
Rationale: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC. Patient concerns: A 73-year-old Japanese man diagnosed with a large HCC was treated with atezolizumab plus bevacizumab. After 2 cycles, he had fever and fatigue and was admitted to the hospital. Diagnosis: Abdominal contrast-enhanced computed tomography revealed tumor necrosis in HCC with gas formation in the necrotic area. Laboratory examination revealed a white blood cell (WBC) count of 16,340/μL and C-reactive protein (CRP) level of 33.0 mg/dL. Based on the above findings, he was diagnosed with a liver abscess. Interventions: Percutaneous transhepatic liver abscess drainage and broad-spectrum antibiotics treatment were performed. Outcomes: Despite liver abscess drainage, persistent fever and no improvement in the WBC count or CRP level was observed. The patient's respiratory condition and renal function gradually worsened; The patient's general condition did not improve despite the ventilator support and continuous hemodiafiltration, and he died on day 37. Lessons: We report the first case of liver abscess after atezolizumab plus bevacizumab treatment for unresectable HCC.
-
Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older Reviewed
Komaki Y, Ozono Y, Nakamura K, Iwakiri H, Hasuike S, Sueta M, Miike T, Yamamoto S, Uto H, Kusumoto K, Ochiai T, Kato J, Komada N, Kuroki K, Eto T, Shigehira M, Hirono S, Nagata K, Kawakami H.
BMC Gastroenterol 28 ( 22 ) 2022.5
Language：English Publishing type：Research paper (scientific journal)
Books 【 display / non-display 】
-
看護のための最新医学講座 肝・胆・膵疾患
坪内 博仁,蓮池 悟（ Role： Joint author , 主要症候とその発生機序 黄疸、腹水、吐下血、肝脾腫、肝生脳症、出血傾向、皮膚症状）
中山書店 2005.3
Language：Japanese Book type：Scholarly book
-
分子消化器病学研究会 第12回浜名湖シンポジウム記録集
坪内 佳子,井戸 章雄,宇都 浩文,沼田 政嗣,森内 昭博,金 一徳,蓮池 悟,永田 賢治,林 克裕,坪内 博仁（ Role： Joint author , 遺伝性高αフェトプロテイン血症の二家系における遺伝子解析）
アークメディア 2005.12
Language：Japanese Book type：Scholarly book
-
敗血症の診断/治療の実状と病態・メカニズムをふまえた開発戦略
蓮池悟, 大園芳範, 下田和哉（ Role： Joint author）
技術情報協会 2013.8
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
Managements for chronic liver failure due to liver cirrhosis
Ido A,Hasuike S,Nagata K,Tsubouchi H
54 ( 3 ) 599 - 605 2005.3
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Diagnosis and treatment strategy of fulminant hepatic failure
Hasuike S,Ido A,Uto H,Tsubouchi H
51 ( 1 ) 37 - 45 2005.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Streptococcus constellatusによる肝膿瘍をきたした小腸GISTの１例 （共著）
三池忠, 山本章二朗, 田原良博, 蓮池悟, 船ヶ山まゆみ, 前原直樹, 田中弘之, 秋山裕, 千々岩一男, 下田和哉
日本消化器病学会雑誌 2014.7
Language：Japanese Publishing type：Research paper, summary (national, other academic conference) Publisher： 一般財団法人 日本消化器病学会
-
Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection
Kawano N,Hasuike S, Iwakiri H, Nakamura K, Ozono Y, Kusumoto H, Nagata K,Kikuchi I, Yoshida S, Kuriyama T,Yamashita K, Muranaka T, Kawaguchi T, Sata M, Okamura T, Ueda A, Shimoda K
Journal of Clinical and Experimental Hematopathology .53(2) 2013.8
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：日本リンパ網内系学会
-
Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with membranous nephropathy treated with immunosuppression ["jointly worked"]
54 ( 1 ) 74 - 80 2013.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
Presentations 【 display / non-display 】
-
潰瘍性大腸炎術後13年目に発症し、インフリキシマブが奏功した重度の回腸嚢炎の1例
佐々木良子、山本章二朗、安倍弘生、野田裕子、野田貴穂、鈴木翔、上原なつみ、竹田幸子、坂口舞、夏田朱一郎、橋本神奈、前村幸輔、山路卓巳、三池忠、岩切久芳、田原良博、蓮池悟、永田賢治、下田和哉
第104回日本消化器病学会九州支部例会 (大分市) 日本消化器病学会九州支部
Event date： 2014.12.5 - 2014.12.6
Language：Japanese Presentation type：Oral presentation (general)
Venue：大分市
-
テラプレビル3剤併用療法施行患者におけるHCV薬剤耐性遺伝子変異と治療成績に関する検討
大園芳範、永田賢治、山田優里、土持舞依、岩切久芳、末田光恵、蓮池悟、楠元寿典、下田和哉
第104回日本消化器病学会九州支部例会 (大阪市) 日本消化器病学会九州支部
Event date： 2014.12.5 - 2014.12.6
Language：Japanese Presentation type：Oral presentation (general)
Venue：大阪市
-
胃全摘後に生じた食道空腸吻合部静脈瘤の1例
野田貴穂、岩切久芳、野田裕子、山田優里、大園芳範、土持舞依、山本章二朗、蓮池悟、永田賢治、下田和哉
第104回日本消化器病学会九州支部例会 (大分市) 日本消化器病学会九州支部
Event date： 2014.12.5 - 2014.12.6
Language：Japanese Presentation type：Oral presentation (general)
Venue：大分市
-
家族性地中海熱非典型例の加療中に腸管ベーチェット病を合併した1幼児例
平田智也、山本章二朗、野田貴穂、野田裕子、鈴木翔、上原なつみ、竹田幸子、夏田朱一郎、坂口舞、前村幸輔、橋本神奈、山路卓巳、三池忠、安倍弘生、岩切久芳、田原良博、蓮池悟、永田賢治、下田和哉
第104回日本消化器病学会九州支部例会 (大分市) 日本消化器病学会九州支部
Event date： 2014.12.5 - 2014.12.6
Language：Japanese Presentation type：Oral presentation (general)
Venue：大分市
-
本態性血小板増多症により肝外門脈閉塞症をきたし、繰り返す静脈瘤出血に対して脾摘術後ハイドレアを投与した1例
興梠聡志、永田賢治、山田優里、大園芳範、土持舞依、岩切久芳、末田光恵、蓮池悟、大谷和広、近藤千博、下田和哉
第104回日本消化器病学会九州支部例会 (大分市) 日本消化器病学会九州支部
Event date： 2014.12.5 - 2014.12.6
Language：Japanese Presentation type：Oral presentation (general)
Venue：大分市
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
遺伝子改変動物を用いたオステオアクチビンの肝発癌・線維化に及ぼす影響の解析
2005.04 - 2006.03
科学研究費補助金 若手研究(B)
Authorship：Principal investigator
遺伝子改変動物を用いたオステオアクチビンの肝発癌・線維化に及ぼす影響の解析を行った。
-
遺伝子改変動物を用いたオステオアクチビンの肝発癌・線維化に及ぼす影響の解析
2005.04
科学研究費補助金 若手研究(B)
Authorship：Principal investigator
遺伝子改変動物を用いたオステオアクチビンの肝発癌・線維化に及ぼす影響の解析を行った。